Print Published 1st Feb 2017, 14:43

Cello spends initial $5.75m on US health business

Cello Group is raising about £14.1 million, net of expenses, from share placings on the London stock market and is using some of that money to buy the assets of a US strategic advisory consultancy serving US, European and other overseas biotech and healthcare clients.

The share placings are in two stages.  The first £5 million has already been raised and the remaining shares will be issued when Cello has obtained approval at a shareholders’ meeting planned for 17 February.